BioLive Wire · AI-collected
BioNTech Drops 10% on mRNA Trial Failure, Highlighting Moderna Contrast
- BioNTech shares dropped 10% on an mRNA trial failure, highlighting a contrast with Moderna, according to Investing.com.
Published Aug 28Source: Investing.com ↗